Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 143-155 |
| Number of pages | 13 |
| Journal | Psychosis |
| Volume | 8 |
| Issue number | 2 |
| Early online date | 28 Oct 2015 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
Keywords
- schizophrenia
- depression
- randomised controlled trial
- pilot
- acceptanc and commitment therapy
Cite this
}
A parallel group randomised open blinded evaluation of acceptance and commitment therapy for depression after psychosis : a pilot trial protocol (ADAPT). / Gumley, Andrew; White, Ross; Briggs, Andy; Ford, Ian; Barry, Sarah; Stewart, Corinna; Beedie, Sara; Clarke, Caoimhe; Macleod, Rachel; Lidstone, Emma; McLeod, Hamish.
In: Psychosis, Vol. 8, No. 2, 2016, p. 143-155.Research output: Contribution to journal › Article
TY - JOUR
T1 - A parallel group randomised open blinded evaluation of acceptance and commitment therapy for depression after psychosis
T2 - a pilot trial protocol (ADAPT)
AU - Gumley, Andrew
AU - White, Ross
AU - Briggs, Andy
AU - Ford, Ian
AU - Barry, Sarah
AU - Stewart, Corinna
AU - Beedie, Sara
AU - Clarke, Caoimhe
AU - Macleod, Rachel
AU - Lidstone, Emma
AU - McLeod, Hamish
PY - 2016
Y1 - 2016
N2 - Background: Depression is one of the major contributors to poorer quality of life among individuals with psychosis and schizophrenia. Aims: This study protocol was designed as a pilot trial to determine the parameters of a larger, definitive pragmatic multi-centre randomised controlled trial of Acceptance and Commitment Therapy for depression after psychosis (ACTdp) for individuals with a diagnosis of schizophrenia who also meet diagnostic criteria for major depression. Methods: The study protocol was registered before initiating recruitment and was designed as a Parallel-group Randomised Open Blinded Evaluation (PROBE) comparing ACTdp plus standard care (SC) or SC alone. Participants were required to meet DSM-IV-TR criteria for schizophrenia and major depression (confirmed by Structured Clinical Interview for DSM/SCID-I and Calgary Depression Scale for Schizophrenia; score gt; 7). Blinded follow-ups are undertaken at 5 months (end of treatment) and at 10 months (5 months post treatment). Implications: The pilot aims to establish the basis for a larger-scale multi-centre randomised controlled trial of ACTdp. The most important study outcomes that will provide the basis of informing progression to a full trial are identified a priori as Population, Intervention, Control and Outcomes (PICO).
AB - Background: Depression is one of the major contributors to poorer quality of life among individuals with psychosis and schizophrenia. Aims: This study protocol was designed as a pilot trial to determine the parameters of a larger, definitive pragmatic multi-centre randomised controlled trial of Acceptance and Commitment Therapy for depression after psychosis (ACTdp) for individuals with a diagnosis of schizophrenia who also meet diagnostic criteria for major depression. Methods: The study protocol was registered before initiating recruitment and was designed as a Parallel-group Randomised Open Blinded Evaluation (PROBE) comparing ACTdp plus standard care (SC) or SC alone. Participants were required to meet DSM-IV-TR criteria for schizophrenia and major depression (confirmed by Structured Clinical Interview for DSM/SCID-I and Calgary Depression Scale for Schizophrenia; score gt; 7). Blinded follow-ups are undertaken at 5 months (end of treatment) and at 10 months (5 months post treatment). Implications: The pilot aims to establish the basis for a larger-scale multi-centre randomised controlled trial of ACTdp. The most important study outcomes that will provide the basis of informing progression to a full trial are identified a priori as Population, Intervention, Control and Outcomes (PICO).
KW - schizophrenia
KW - depression
KW - randomised controlled trial
KW - pilot
KW - acceptanc and commitment therapy
UR - http://eprints.gla.ac.uk/115819/
U2 - 10.1080/17522439.2015.1100669
DO - 10.1080/17522439.2015.1100669
M3 - Article
VL - 8
SP - 143
EP - 155
IS - 2
ER -